Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.Optimize Your Investment Research with SparkEffectively assess a stock's ...

Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...

In trading on Friday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $24.14, changing hands as high as $24.32 per share. Genmab A/S shares are currently trading ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs on America’s ...

Check Out Our Latest Stock Analysis on GMAB Genmab A/S Stock Up 3.3 % Shares of NASDAQ GMAB opened at $24.10 on Thursday. The stock has a market capitalization of $15.95 billion, a price-to ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes about the stocks. Leerink Partners raised its rating on GMAB to ...